Lyra TherapeuticsLYRA
About: Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Employees: 80
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
20% more funds holding
Funds holding: 51 [Q2] → 61 (+10) [Q3]
5.35% less ownership
Funds ownership: 55.05% [Q2] → 49.7% (-5.35%) [Q3]
10% less capital invested
Capital invested by funds: $9.28M [Q2] → $8.36M (-$922K) [Q3]
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
Research analyst outlook
We haven’t received any recent analyst ratings for LYRA.
